ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO809

Pretransplant Inflammatory Biomarkers Predict Death-Censored Graft Failure after Kidney Transplantation

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Lorenz, Elizabeth C., Baylor College of Medicine, Houston, Texas, United States
  • Smith, Byron H., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Tapia, Amanda L., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Park, Walter, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Stegall, Mark D., Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background

Pre-transplant inflammatory biomarkers have previously been associated with adverse kidney transplant (KT) outcomes, including delayed graft function and acute rejection. The goal of this study was to determine if pre-KT inflammatory biomarkers are also associated with graft failure after KT.

Methods

We retrospectively measured inflammatory biomarker levels in serum collected up to 1 year prior to KT in recipients transplanted at Mayo Clinic in Rochester, Minnesota between 1/2006-12/2018.The following biomarkers were chosen based on their association with medical risk across multiple patient populations: interleukin-15 (IL-15), IL-1β, monocyte chemoattractant protein-1 (MCP-1), growth differentiation factor-15 (GDF-15), IL-6, monokine induced by gamma interferon/chemokine (C-X-C motif) ligand 9 (MIG/CXCL9), soluble FAS (sFAS), soluble tumor necrosis factor receptor-1 (sTNF-R1), and TNFα. Biomarker levels were normalized with Z-transformation. Kaplan-Meier estimation and Cox regression were used to examine the relationship between biomarkers and death-censored graft failure.

Results

Our cohort consisted of 1,595 KT recipients with a mean age of 52.0 ± 14.2 years; 62.9% were male and 83.2% were White. Over a mean follow-up of 7.4 ± 3.9 years, 10.4% of patients (n=166) experienced death-censored graft failure. Higher pre-KT levels of soluble tumor necrosis factor receptor-1 (sTNF-R1) were significantly associated with death-censored graft failure after adjusting for other biomarkers (HR 1.4 per standardized log-value, 95% CI 1.2-1.7, p=0.0006).

Conclusion

Pre-KT activation of TNF pathways may contribute to graft failure following KT. Measuring pre-KT serum concentrations of sTNF-R1 may help to risk stratify and manage patients undergoing KT.

Funding

  • NIDDK Support